Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192215 · ClinicalTrials.gov registry record · Phase 3
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
A Phase 3 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT03192215: Clinical Trial Phase 3 study, sponsored by Columbia University.
NCT03192215 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1,015 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03192215, a Phase 3 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
Objectives * Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. * Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Primary Outcome
Participants were monitored for up to 5 years of study participation. This is the number of participants who had recurrent stroke of any type (ischemic, hemorrhagic, or of unclear type).
Interventions
- DRUG Aspirin
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2023-04-17 |
| Phase | Phase 3 |
Why NCT03192215 stopped before completion
NCT03192215 is an interventional study that assigns participants to a tested intervention. Its 1,015 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT03192215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03192215 about?
NCT03192215 is a clinical study titled "AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke". Objectives * Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. * Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the se...
What is the current status of trial NCT03192215?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2018-01-19. Estimated completion is 2023-04-17.
What interventions are being tested in trial NCT03192215?
The interventions under investigation include: Aspirin (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT03192215?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03192215's enrollment target sits among peer trials
1,015 294th of 2000 higher than 1,707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI